Advertisement
ADVANCED SEARCH

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gutfreund, K. S. Articles by Bain, V. G. Search for Related Content PubMed PubMed Citation Articles by Gutfreund, K. S. Articles by Bain, V. G. Related Collections Drugs: gastrointestinal system Liver (including hepatitis and cirrhosis)

Chronic viral hepatitis C: management update

From the Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alta.

Abstract

The management of chronic viral hepatitis C is evolving rapidly. Monotherapy with interferon, the accepted standard of treatment until recently, achieves only a modest sustained virological response rate of 15%. Combination treatment with alpha-2b interferon and ribavirin has been shown to increase sustained response rates to 40% in patients who have never been treated with interferon and to 50% in those who have relapsed following monotherapy with interferon. However, side effects, which have led to the discontinuation of combination treatment in a significant proportion of patients, must be carefully monitored. Treatment with interferon alpha-2b and ribavirin has now been approved in Canada, but the selection and monitoring of patients suitable for combination treatment requires special expertise. Although improvements in current therapeutic options may be possible with more frequent, higher doses or long-acting forms of interferon together with ribavirin, low sustained response rates (i.e., below 30%) for patients with hepatitis C virus genotype 1 emphasize the need for novel antiviral medications that will target the functional sites of the HCV genome.

This article has been cited by other articles:

				J. G. McHutchison, G. Dusheiko, M. L. Shiffman, M. Rodriguez-Torres, S. Sigal, M. Bourliere, T. Berg, S. C. Gordon, F. M. Campbell, D. Theodore, et al. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C N. Engl. J. Med., November 29, 2007; 357(22): 2227 - 2236. [Abstract] [Full Text] [PDF]

				G. V. Villanova, D. Gardiol, M. A. Taborda, V. Reggiardo, H. Tanno, E. D. Rivadeneira, G. R. Perez, and A. A. Giri Strategic Approach To Produce Low-Cost, Efficient, and Stable Competitive Internal Controls for Detection of RNA Viruses by Use of Reverse Transcription-PCR J. Clin. Microbiol., November 1, 2007; 45(11): 3555 - 3563. [Abstract] [Full Text] [PDF]

				T. Wong and S. S. Lee Hepatitis C: a review for primary care physicians Can. Med. Assoc. J., February 28, 2006; 174(5): 649 - 659. [Abstract] [Full Text] [PDF]

				V. E. Buckwold Implications of finding synergic in vitro drug-drug interactions between interferon-{alpha} and ribavirin for the treatment of hepatitis C virus J. Antimicrob. Chemother., March 1, 2004; 53(3): 413 - 414. [Abstract] [Full Text] [PDF]

				V. E. Buckwold, J. Wei, M. Wenzel-Mathers, and J. Russell Synergistic In Vitro Interactions between Alpha Interferon and Ribavirin against Bovine Viral Diarrhea Virus and Yellow Fever Virus as Surrogate Models of Hepatitis C Virus Replication Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2293 - 2298. [Abstract] [Full Text] [PDF]

				J. Hoey Early treatment of acute hepatitis C infection may lead to cure Can. Med. Assoc. J., November 1, 2001; 165(11): 1527 - 1527. [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2000, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.